CDKN2D, cyclin dependent kinase inhibitor 2D, 1032

N. diseases: 110; N. variants: 2
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0033860
Disease: Psoriasis
Psoriasis
0.100 Biomarker disease BEFREE Tildrakizumab (tildrakizumab-asmn in the USA) [Ilumetri<sup>®</sup>; Ilumya™] is a humanized monoclonal antibody (mAb) that selectively targets the p19 subunit of interleukin (IL)-23, thereby inhibiting the IL-23/IL-17 axis, the signalling pathway primarily implicated in the immunopathogenesis of psoriasis. 30924030 2019
CUI: C0033860
Disease: Psoriasis
Psoriasis
0.100 Biomarker disease BEFREE Tildrakizumab is a humanized IgG1 monoclonal antibody targeting interleukin-23 p19 and is approved for use in moderate to severe psoriasis. 30394141 2019
CUI: C0033860
Disease: Psoriasis
Psoriasis
0.100 GeneticVariation disease BEFREE Tildrakizumab, an inhibitor of the p19 subunit of interleukin (IL)-23, was recently Food and Drug Administration (FDA) approved for patients with moderate to severe psoriasis. 30345790 2019
CUI: C0033860
Disease: Psoriasis
Psoriasis
0.100 Biomarker disease BEFREE Since the identification of high levels of interleukin 23 (IL- 23) in psoriasis lesional skin, as well as finding that IL-23 was the most important source of the p40 subunit shared by IL-12 and IL-23, significant effort has been made in identifying potential new drugs that specifically block the unique IL-23 p19 subunit. 30215632 2018
CUI: C0033860
Disease: Psoriasis
Psoriasis
0.100 Biomarker disease BEFREE Guselkumab (GUS) is a subcutaneously administered monoclonal antibody that targets the p19 cytokine subunit in IL-23 and IL-39 and is US Food and Drug Administration (FDA) approved for the treatment of moderate-to-severe psoriasis in adult patients. 30174431 2018
CUI: C0033860
Disease: Psoriasis
Psoriasis
0.100 Biomarker disease BEFREE Areas covered: We review the main adverse events associated with the biologic agents currently available for the treatment of psoriasis and the new inhibitors targeting the p19 subunit of interleukin (IL) 23 and the IL-17A receptor. 29557200 2018
CUI: C0033860
Disease: Psoriasis
Psoriasis
0.100 Biomarker disease BEFREE Guselkumab, a human monoclonal antibody that binds to the p19 subunit of interleukin 23, has been approved for the treatment of moderate-to-severe psoriasis. 29893222 2018
CUI: C0033860
Disease: Psoriasis
Psoriasis
0.100 Biomarker disease BEFREE Interleukin-23 (IL-23), a heterodimeric cytokine of covalently bound p19 and p40 proteins, has recently been closely associated with development of several chronic autoimmune diseases such as psoriasis, psoriatic arthritis or inflammatory bowel disease. 28100093 2017
CUI: C0033860
Disease: Psoriasis
Psoriasis
0.100 Biomarker disease BEFREE Selective Interleukin-23 p19 Inhibition: Another Game Changer in Psoriasis? Focus on Risankizumab. 28770513 2017
CUI: C0033860
Disease: Psoriasis
Psoriasis
0.100 AlteredExpression disease BEFREE Increased IL-23 p19 mRNA levels were observed for both EN-like lesions of patients with BD and skin lesions of patients with psoriasis compared with normal individuals. 18205865 2008